

Vitrakvi - (25 mg and 100 mg ; Capsule)

Generic Name	Larotrectinib Sulfate	Innovator	Bayer
Dosage	25 mg and 100 mg ; Capsule	Branded US Sales	Less Than \$1000 mn
Probable FTF	Less Than 5	Known Para IV Filers	Less Than 5
Other ANDA developers	Less Than 5	Tentative Approvals	Less Than 5
Final Approvals	None	Generic Launches	None
Indication	VITRAKVI is a kinase inhibitor indicated for the treatment of adult and pediatric patients with solid tumors that: ? have a neurotrophic receptor tyrosine kinase (NTRK) gene fusion without a known acquired resistance mutation, ? are metastatic or where surgical resection is likely to result in severe morbidity, and ? have no satisfactory alternative treatments or that have progressed following treatment.		
Complexities	Yes		

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

Executive Summary

Please Contact contact@researchdelta.com to get Detailed Information.

Patent Status

Please Contact contact@researchdelta.com to get Detailed Information.

Launch Timelines and Competition

Please Contact contact@researchdelta.com to get Detailed Information.

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

Vitrakvi - (EQ 20MG BASE/ML ; Solution)

Generic Name	Larotrectinib Sulfate	Innovator	Bayer
Dosage	EQ 20MG BASE/ML ; Solution	Branded US Sales	Less Than \$1000 mn
Probable FTF	None	Known Para IV Filers	None
Other ANDA developers	Less Than 5	Tentative Approvals	None
Final Approvals	None	Generic Launches	None
Indication	VITRAKVI is a kinase inhibitor indicated for the treatment of adult and pediatric patients with solid tumors that: ? have a neurotrophic receptor tyrosine kinase (NTRK) gene fusion without a known acquired resistance mutation, ? are metastatic or where surgical resection is likely to result in severe morbidity, and ? have no satisfactory alternative treatments or that have progressed following treatment.		
Complexities	Yes		

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

Executive Summary

Please Contact contact@researchdelta.com to get Detailed Information.

Patent Status

Please Contact contact@researchdelta.com to get Detailed Information.

Launch Timelines and Competition

Please Contact contact@researchdelta.com to get Detailed Information.

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.